We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
-4.96%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$876M
AUM Growth
-$169M
(-16%)
Cap. Flow
-$74.8M
Cap. Flow
% of AUM
-8.55%
Top 10 Holdings %
Top 10 Hldgs %
62.04%
Holding
42
New
6
Increased
11
Reduced
19
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AnaptysBio
ANAB
|
+$62.8M |
| 2 |
NeoGenomics
NEO
|
+$35.9M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$28.1M |
| 4 |
Health Catalyst
HCAT
|
+$27.5M |
| 5 |
Neuropace
NPCE
|
+$19.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FNA
Paragon 28, Inc.
FNA
|
+$125M |
| 2 |
Insmed
INSM
|
+$30.8M |
| 3 |
AtriCure
ATRC
|
+$24.3M |
| 4 |
Pliant Therapeutics
PLRX
|
+$22.1M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
908 Devices
MASS
$329M
| $7.62M | 0.87% |
+1,701,095
| New | +$5.04M |
|
27
Transmedics
TMDX
$2.64B
| $7.26M | 0.83% |
107,860
-31,897
| -23% | -$2.19M |
|
28
Oscar Health
OSCR
$9.41B
| $6.85M | 0.78% |
522,302
-24,520
| -4% | -$364K |
|
|
FNA
29
DELISTED
Paragon 28, Inc.
FNA
| $6.53M | 0.75% |
500,000
-10,080,467
| -95% | -$125M |
|
30
Evolent Health
EVH
$348M
| $5.54M | 0.63% |
585,436
+531,816
| +992% | +$5.37M |
|
|
31
Insmed
INSM
$21.4B
| $5.2M | 0.59% |
68,153
-402,039
| -86% | -$30.8M |
|
32
Tandem Diabetes Care
TNDM
$1.34B
| $4.7M | 0.54% |
245,257
-46,860
| -16% | -$1.37M |
|
33
Insulet
PODD
$11.5B
| $4.47M | 0.51% |
17,022
-16,799
| -50% | -$4.55M |
|
34
Vaxcyte
PCVX
$7.81B
| $3.57M | 0.41% |
+94,420
| New | +$7.55M |
|
35
Senseonics Holdings Inc
SENS
$263M
| $3.06M | 0.35% |
232,875
-88,715
| -28% | -$1.47M |
|
36
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
| $2.3M | 0.26% |
+14,028
| New | +$1.03M |
|
37
Structure Therapeutics
GPCR
$3.41B
| $2.29M | 0.26% |
132,380
-266,475
| -67% | -$6.53M |
|
38
Dyne Therapeutics
DYN
$4.7B
| – | – |
-420,431
| Closed | -$9.91M |
|
39
iShares Russell 2000 Growth ETF
IWO
$14.3B
| – | – |
-1,208
| Closed | -$348K |
|
40
Kymera Therapeutics
KYMR
$8.51B
| – | – |
-383,310
| Closed | -$15.4M |
|
41
Natera
NTRA
$38.3B
| – | – |
-93,088
| Closed | -$14.7M |
|
|
42
Pliant Therapeutics
PLRX
$64.4M
| – | – |
-1,681,110
| Closed | -$22.1M |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, First Light Asset Management held 42 positions worth $876M, down 16% from $1.05B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
First Light Asset Management withdrew a net $74.8M in Q1 2025, closing 5 positions and reducing 19 holdings. Its most notable exit was Pliant Therapeutics, an estimated $22.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.
Against the trend, First Light Asset Management opened a new position in Neuropace worth $19.5M.
- First Light Asset Management's largest Q1 2025 buy was Neuropace: 1,584,048 shares worth $19.5M.
- First Light Asset Management added most to AnaptysBio in Q1 2025, an estimated $62.8M increase.
- First Light Asset Management's biggest Q1 2025 reduction was Paragon 28, Inc., cutting an estimated $125M.
- First Light Asset Management fully exited Pliant Therapeutics in Q1 2025, selling an estimated $22.1M.
- First Light Asset Management's ten largest holdings make up 62% of its $876M portfolio in Q1 2025.
- First Light Asset Management opened 6 new positions and closed 5 in Q1 2025.
- First Light Asset Management's portfolio value fell 16% quarter-over-quarter to $876M.
Based on First Light Asset Management's 13F filing for Q1 2025, filed 15 May 2025.